Blood & Cancer
Hem-Onc News: No benefit from postop radiotherapy in NSCLC, sotorasib is a 'triumph of drug discovery,' and choosing a TKI for ALL
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:13:38
- Mas informaciones
Informações:
Sinopsis
Hematology-Oncology News: No benefit with postoperative radiotherapy in stage IIIA2 NSCLC (https://bit.ly/3i1196r) First-in-class ADC ups survival in mTNBC (https://bit.ly/2GaoVQ2) Sotorasib is a 'triumph of drug discovery' in cancer (https://bit.ly/2FQwpIt) TKI choice key for fit/unfit patients with Ph+ALL (https://bit.ly/3kLdmOs) Email Blood & Cancer at podcasts@mdedge.com
